ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Zhang X, Liu Y, Zhao L, Li B, Yu H, Wen H, Yu XJ, 2013. An emerging hemorrhagic fever in China caused by a novel bunyavirus SFTSV. Sci China Life Sci 56: 697–700.
-
2.
Zhang SF et al. 2019. Rickettsia typhi infection in severe fever with thrombocytopenia patients, China. Emerg Microbes Infect 8: 579–584.
-
3.
Kohl C. et al., 2020. Zwiesel bat banyangvirus, a potentially zoonotic Huaiyangshan banyangvirus (formerly known as SFTS)–like banyangvirus in northern bats from Germany. Sci Rep 10: 1370.
-
4.
Yu XJ et al. 2011. Fever with thrombocytopenia associated with a novel bunyavirus in China. New Engl J Med 364: 1523–1532.
-
5.
Shin J, Kwon D, Youn SK, Park JH, 2015. Characteristics and factors associated with death among patients hospitalized for severe fever with thrombocytopenia syndrome, South Korea, 2013. Emerg Infect Dis 21: 1704–1710.
-
6.
Tran XC, Yun Y, Van An L, Kim SH, Thao NTP, Man PKC, Yoo JR, Heo ST, Cho NH, Lee KH, 2019. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis 25: 1029–1031.
-
7.
Takahashi T et al. 2014. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis 209: 816–827.
-
8.
Sun J, Lu L, Wu H, Yang J, Ren J, Liu Q, 2017. The changing epidemiological characteristics of severe fever with thrombocytopenia syndrome in China, 2011–2016. Sci Rep 7: 9236.
-
9.
Zhan J, Wang Q, Cheng J, Hu B, Li J, Zhan F, Song Y, Guo D, 2017. Current status of severe fever with thrombocytopenia syndrome in China. Virol Sin 32: 51–62.
-
10.
Gong L et al. 2018. Human-to-human transmissions of severe fever with thrombocytopenia syndrome virus in Anhui province, 2010–2017. Clin Microbiol Infect 24: 920–922.
-
11.
Li DX, 2015. Severe fever with thrombocytopenia syndrome: a newly discovered emerging infectious disease. Clin Microbiol Infect 21: 614–620.
-
12.
Liu S, Chai C, Wang C, Amer S, Lv H, He H, Sun J, Lin J, 2014. Systematic review of severe fever with thrombocytopenia syndrome: virology, epidemiology, and clinical characteristics. Rev Med Virol 24: 90–102.
-
13.
Gai ZT et al. 2012. Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients. J Infect Dis 206: 1095–1102.
-
14.
Cui F, Cao HX, Wang L, Zhang SF, Ding SJ, Yu XJ, Yu H, 2013. Clinical and epidemiological study on severe fever with thrombocytopenia syndrome in Yiyuan county, Shandong province, China. Am J Trop Med Hyg 88: 510–512.
-
15.
Zhao L et al. 2012. Severe fever with thrombocytopenia syndrome virus, Shandong province, China. Emerg Infect Dis 18: 963–965.
-
16.
Deng B et al. 2013. Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome bunyavirus infection in Northeast China. PLoS One 8: e80802.
-
17.
Se Yoon P, Choi WY, Chong YP, Park SW, Wang EB, Lee WJ, Jee Y, Kwon SW, Kim SH, 2016. Use of plasma therapy for severe fever with thrombocytopenia syndrome encephalopathy. Emerg Infect Dis 22: 1306–1307.
-
18.
Gong L et al. 2019. Knowledge, attitudes, and practices regarding severe fever with thrombocytopenia syndrome in endemic areas of Anhui province, eastern China. Am J Trop Med Hyg 100: 652–658.
-
19.
Gong L et al. 2019. Socioeconomic burden of severe fever with thrombocytopenia syndrome in endemic areas of Anhui province, eastern China. Zoonoses Public Health 66: 879–885.
-
20.
Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J, 2010. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41: 61.
-
21.
Robles NJC, Han HJ, Park SJ, Choi YK, 2018. Epidemiology of severe fever and thrombocytopenia syndrome virus infection and the need for therapeutics for the prevention. Clin Exp Vaccin Res 7: 43–50.
-
22.
Cui N et al. 2015. Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis. J Infect 70: 52–59.
-
23.
Liu K et al. 2015. A national assessment of the epidemiology of severe fever with thrombocytopenia syndrome, China. Sci Rep 5: 9679.
-
24.
Wang L et al. 2019. A nomogram to predict mortality in patients with severe fever with thrombocytopenia syndrome at the early stage-A multicenter study in China. Plos Negl Trop Dis 13: e0007829.
-
25.
Cui N et al. 2014. Clinical progression and predictors of death in patients with severe fever with thrombocytopenia syndrome in China. J Clin Virol 59: 12–17.
-
26.
Jin C et al. 2012. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model. Proc Natl Acad Sci U S A 109: 10053–10058.
-
27.
Kato H, Yamagishi T, Shimada T, Matsui T, Shimojima M, Saijo M, Oishi K; SFTS Epidemiological Research Group-Japan, 2016. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013–2014. PLoS One 11: e0165207.
-
28.
Kim J, Bae JM, 2019. Epidemiological and clinical characteristics of confirmed cases of severe fever with thrombocytopenia syndrome in Jeju province, Korea, 2014–2018. J Prev Med Public Health 52: 195–199.
-
29.
Liu W et al. 2013. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with thrombocytopenia syndrome. Clin Infect Dis 57: 1292–1299.
Clinical Progress and Risk Factors for Death from Severe Fever with Thrombocytopenia Syndrome: A Multihospital Retrospective Investigation in Anhui, China
ABSTRACT
Knowledge of the clinical progress of severe fever with thrombocytopenia syndrome (SFTS) and the associated predictors of mortality is important for providing appropriate treatment in severe cases. A multihospital retrospective study was conducted in three SFTS-endemic cities, in 2018. Of the 208 SFTS-confirmed cases, there were 189 survivors and 19 deaths. The median age was 64 years; 104 (50.0%) patients were men, and 188 (90.4%) were farmers. Furthermore, 203 (97.6%) patients reported fever and 70 (33.7%) reported fatigue. Most fatal cases had complications including multiple-organ failure, central nervous syndrome (CNS) abnormalities, and disseminated intravascular coagulation. During the fever phase, alanine transaminase, aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, D-dimer, glucose, hydroxybutyrate dehydrogenase, lactate dehydrogenase (LDH), procalcitonin, prothrombin time, and uric acid levels were higher in fatal than in nonfatal cases (P < 0.05). Creatine kinase (CK), CK-MB (CKMB), AST, and LDH levels were significantly lower in nonfatal than in fatal cases (P < 0.05). Central nervous syndrome abnormalities (odds ratio [OR] = 20.9, 95% CI: 4.3, 100), body temperature ≥ 38.5°C (OR = 23.2, 95% CI: 3.4, 158), BUN levels ≥ 6.4 mmol/L (OR = 9.9, 95% CI: 2.2, 44), CKMB levels ≥ 100 U/L (OR = 33.2, 95% CI: 5.8, 192), and LDH levels ≥ 1,000 U/L (OR = 8.3, 95% CI: 1.9, 37) were predictors of mortality. Our findings reveal that the presence of specific complications and laboratory parameters may serve as predictors of mortality and aid in early identification of severe SFTS cases in clinical practice.
Author Notes
Financial support: This study was supported by a grant of Anhui Provincial Department of Science and Technology, Anhui Provincial Health Commission Emergency Research Project of Novel Coronavirus Infection (Grant numbers 202004a07020002; 202004a07020004).
Authors’ addresses: Lei Gong, Jiabing Wu, Siqi Lu, Meng Zhu, Dandan Song, Bin Su, and Zhirong Liu, Anhui Provincial Center for Disease Control and Prevention, Hefei, China, E-mails: gong0516@sina.com, wjb0386@163.com, yuanruoqi@163.com, mengmeng11280904@126.com, dandansodan@126.com, sub602@sina.com, and liuzhirong66@126.com. Lei Zhang, Hefei Municipal Center for Disease Control and Prevention, Hefei, China, E-mail: 469022307@qq.com. Yong Lyu, Lu’an Municipal Center for Disease Control and Prevention, Lu’an, China, E-mail: lyong@lacdc.com.cn. Boxi Liu, Inner Mongolia Autonomous Regional Center for Disease Control and Prevention, Hohhot, China, E-mail: only_lbx@qq.com. Yuliang Zhu, Heilongjiang Provincial Center for Disease Control and Prevention, Harbin, China. E-mail: 348137217@qq.com.
These authors contributed equally to this work.